Focused on discovery and development of therapeutic fusion proteins based on its proprietary Elastin-Like Polypeptide (ELP) technology
- Year invested 2009
- Investment Stage Early
- Sectors
- Investment Status Current
- Website phasebio.com
- Company Status IPO/Public (NASDAQ: PHAS)